Literature DB >> 33589796

NOD-like receptors in autoimmune diseases.

Li Chen1,2, Shi-Qi Cao1,2, Ze-Min Lin1, Shi-Jun He3,4, Jian-Ping Zuo5,6,7.   

Abstract

Autoimmune diseases are chronic immune diseases characterized by dysregulation of immune system, which ultimately results in a disruption in self-antigen tolerance. Cumulative data show that nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) play essential roles in various autoimmune diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, multiple sclerosis (MS), etc. NLR proteins, consisting of a C-terminal leucine-rich repeat (LRR), a central nucleotide-binding domain, and an N-terminal effector domain, form a group of pattern recognition receptors (PRRs) that mediate the immune response by specifically recognizing cellular pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) and triggering numerous signaling pathways, including RIP2 kinase, caspase-1, nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK) and so on. Based on their N-terminal domain, NLRs are divided into five subfamilies: NLRA, NLRB, NLRC, NLRP, and NLRX1. In this review, we briefly describe the structures and signaling pathways of NLRs, summarize the recent progress on NLR signaling in the occurrence and development of autoimmune diseases, as well as highlight numerous natural products and synthetic compounds targeting NLRs for the treatment of autoimmune diseases.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  NOD-like receptors; autoimmune diseases; botanicals; inflammasomes; inhibitors; pattern recognition receptors

Mesh:

Substances:

Year:  2021        PMID: 33589796      PMCID: PMC8564530          DOI: 10.1038/s41401-020-00603-2

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  134 in total

Review 1.  Pattern recognition receptors and inflammation.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

Review 3.  Innate receptors for adaptive immunity.

Authors:  Marie-Cécile Michallet; Giorgia Rota; Kendle Maslowski; Greta Guarda
Journal:  Curr Opin Microbiol       Date:  2013-05-07       Impact factor: 7.934

Review 4.  Evolutionary Convergence and Divergence in NLR Function and Structure.

Authors:  Etienne Meunier; Petr Broz
Journal:  Trends Immunol       Date:  2017-05-31       Impact factor: 16.687

Review 5.  Visualising pattern recognition receptor signalling.

Authors:  Charlotte Macleod; Clare E Bryant
Journal:  Biochem Soc Trans       Date:  2017-08-24       Impact factor: 5.407

Review 6.  Targeting pattern-recognition receptors to discover new small molecule immune modulators.

Authors:  Gengzheng Zhu; Yao Xu; Xiaohong Cen; Kutty Selva Nandakumar; Shuwen Liu; Kui Cheng
Journal:  Eur J Med Chem       Date:  2017-12-08       Impact factor: 6.514

Review 7.  Human autoimmune diseases: a comprehensive update.

Authors:  Lifeng Wang; Fu-Sheng Wang; M Eric Gershwin
Journal:  J Intern Med       Date:  2015-07-25       Impact factor: 8.989

Review 8.  NLRC5, at the Heart of Antigen Presentation.

Authors:  Andreas Neerincx; Wilson Castro; Greta Guarda; Thomas A Kufer
Journal:  Front Immunol       Date:  2013-11-22       Impact factor: 7.561

Review 9.  NLRP3 Inflammasome and Inflammatory Bowel Disease.

Authors:  Yu Zhen; Hu Zhang
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

Review 10.  NOD Signaling and Cell Death.

Authors:  Valentin J Heim; Che A Stafford; Ueli Nachbur
Journal:  Front Cell Dev Biol       Date:  2019-10-02
View more
  8 in total

Review 1.  Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases.

Authors:  Jun Liu; Hui Zhang; Yanhong Su; Baojun Zhang
Journal:  Cell Biosci       Date:  2022-05-26       Impact factor: 9.584

Review 2.  The "mitochondrial stress responses": the "Dr. Jekyll and Mr. Hyde" of neuronal disorders.

Authors:  Simone Patergnani; Giampaolo Morciano; Marianna Carinci; Sara Leo; Paolo Pinton; Alessandro Rimessi
Journal:  Neural Regen Res       Date:  2022-12       Impact factor: 6.058

Review 3.  Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis.

Authors:  Qi Jiang; Xin Wang; Enyu Huang; Qiao Wang; Chengping Wen; Guocan Yang; Liwei Lu; Dawei Cui
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 4.  Nod-like Receptors: Critical Intracellular Sensors for Host Protection and Cell Death in Microbial and Parasitic Infections.

Authors:  Abdulkareem Olarewaju Babamale; Szu-Ting Chen
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

5.  Predictive value of drug efficacy by M6A modification patterns in rheumatoid arthritis patients.

Authors:  Shan Song; Rong Zhao; Jun Qiao; Jia Liu; Ting Cheng; Sheng-Xiao Zhang; Xiao-Feng Li
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

Review 6.  Role of NLRP3 inflammasome in systemic sclerosis.

Authors:  Cong Lin; Zhixing Jiang; Ling Cao; Hejian Zou; Xiaoxia Zhu
Journal:  Arthritis Res Ther       Date:  2022-08-16       Impact factor: 5.606

7.  Identification of Significant Genes and Pathways for the Chronic and Subacute Cutaneous Lupus Erythematosus via Bioinformatics Analysis.

Authors:  Yan Teng; Sujing Li; Yang Ding; Yibin Fan; Miao He; Hengzhen Li; Xiaohua Tao; Youming Huang
Journal:  Dis Markers       Date:  2022-09-29       Impact factor: 3.464

8.  Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells.

Authors:  Jing Xie; Long Fan; Liya Xiong; Peiyu Chen; Hongli Wang; Huan Chen; Junhong Zhao; Zhaohui Xu; Lanlan Geng; Wanfu Xu; Sitang Gong
Journal:  BMC Pharmacol Toxicol       Date:  2021-07-15       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.